-
-
-
In selected patients, cardiac resynchronization therapy with a pacemaker or pacemaker-defibrillator improves their clinical course and the addition of a defibrillator with cardiac resynchronization therapy alone further reduces mortality.
-
Current rofecoxib use was associated with a higher risk of acute myocardial infarction or admission for heart failure compared to celecoxib.
-
The Workgroup for Electronic Data Interchange (WEDI), which advises the Department of Health and Human Services (HHS) on issues related to administrative simplification under HIPAA, says the agency should show continued patience as covered entities continue to make progress in implementation of the HIPAA transactions and code sets (TCS) requirements.
-
University of Michigan (UM) researchers said at the annual scientific session of the American College of Cardiology held March 7-10 in New Orleans that HIPAA has significantly affected their ability to study heart attack patients after they are discharged from the hospital.
-
Although there are no approved medications to treat levodopa-induced dyskinesias, several strategies are commonly used. Reducing the interval and amount of each dose of levodopa, maximizing the dose
of dopamine agonists, and even liquefying the daily levodopa and giving it in small hourly increments are useful in selected patients. The present study evaluates clozapine in a double-blind, placebo-controlled trial as a treatment for levodopa-induced dyskinesias.
-
-
Although infectious agents are not widely believed to be the primary cause of Alzheimers disease (AD), some evidence implicates certain neurotrophic viruses and bacteria as possible contributing factors. Canadian investigators Loeb and colleagues suggest that Chlamydia pneumonia infection might play a role in AD. They carried out a randomized, blinded, and placebo-controlled trial testing whether antichlamydial antibiotics (rifampin/doxycycline) could serve as a potential therapy for patients with mild-to-moderate AD.
-
Six patients are the focus of this report defining the neuropathic side effects of thalidomide treatment in multiple myeloma. All patients developed a pure or predominant sensory polyneuropathy while on thalidomide. Thalidomide can induce an axonal sensory neuropathy or, infrequently, a ganglionopathy.
